News
TLTFF
0.150
NaN%
--
Theralase Provides Bladder Cancer Clinical Study Update
Newsfile · 21h ago
Weekly Report: what happened at TLTFF last week (1019-1023)?
Weekly Report · 23h ago
Weekly Report: what happened at TLTFF last week (1012-1016)?
Weekly Report · 10/19 09:29
Weekly Report: what happened at TLTFF last week (1005-1009)?
Weekly Report · 10/12 09:31
Theralase(R) to Present at ThinkEquity Conference
Newsfile · 10/09 11:00
Weekly Report: what happened at TLTFF last week (0928-1002)?
Weekly Report · 10/05 09:31
Weekly Report: what happened at TLTFF last week (0921-0925)?
Weekly Report · 09/28 09:29
Weekly Report: what happened at TLTFF last week (0914-0918)?
Weekly Report · 09/21 09:29
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Newsfile · 09/18 11:00
Weekly Report: what happened at TLTFF last week (0907-0911)?
Weekly Report · 09/14 09:31
Weekly Report: what happened at TLTFF last week (0831-0904)?
Weekly Report · 09/07 09:29
Weekly Report: what happened at TLTFF last week (0824-0828)?
Weekly Report · 08/31 09:31
Theralase Technologies Inc. reports 1H results
Seeking Alpha · 08/28 20:49
Theralase(R) Releases Q2 2026 Financial Statements
Newsfile · 08/28 20:36
Theralase(R) Closes C$3.6 Million Brokered Financing
Newsfile · 08/24 21:01
Weekly Report: what happened at TLTFF last week (0817-0821)?
Weekly Report · 08/24 09:32
Weekly Report: what happened at TLTFF last week (0810-0814)?
Weekly Report · 08/17 09:32
Theralase launches C$5M private placement
Seeking Alpha · 08/10 21:25
Theralase(R) Announces $5 Million Brokered LIFE Offering
Newsfile · 08/10 21:15
Weekly Report: what happened at TLTFF last week (0803-0807)?
Weekly Report · 08/10 09:30
More
Webull provides a variety of real-time TLTFF stock news. You can receive the latest news about Theralase Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLTFF
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.